Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropicpolypeptide (GIP) are incretin hormones with potent stimulatory effects onpostprandial insulin release (Drucker, 2018).GLP-1 receptor (GLP-1R) agonism is an established therapeutic strategy for treatingand managing type 2 diabetes (T2D). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.